Ch3 domain variant or bispecific antibody comprising same
The development of a CH3 domain variant pair with specific amino acid substitutions in bispecific antibodies addresses the challenge of mispairing and improves bispecificity and yield, ensuring effective dual-antigen binding and immune function.
Patent Information
- Application Number
- PCT/KR2024/007030
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current bispecific antibodies face challenges in improving bispecificity and yield due to mispairing issues during production, which affects their ability to effectively bind to multiple antigen proteins simultaneously.
A heterodimer comprising a CH3 domain variant pair with specific amino acid substitutions at targeted positions is developed, enhancing the formation of heterodimers and minimizing homodimer mispairing through the Knob-into-Holes (KiH) technique, thereby improving the bispecificity and yield of the antibodies.
The approach significantly enhances the bispecificity and yield of the antibodies, maintaining target antigen binding ability and immune effector functions while reducing non-specific binding and homodimer formation, thus improving the overall efficacy of the dual-specific antibodies.
Smart Images

Figure KR2024007030_28112024_PF_FP_ABST
Abstract
Description
CH3 domain variant or a bispecific antibody comprising the same
[0001] The present invention relates to a heterodimer comprising a CH3 domain variant pair or a bispecific antibody comprising the same, and more particularly, to a heterodimer employing a CH3 domain variant pair with amino acid substitutions at specific positions or a bispecific antibody comprising the same.
[0002]
[0003] As the various causes and mechanisms of a specific indication are increasingly revealed, a shift from a single target to a multi-target approach is emerging in therapeutic development. Accordingly, for decades, diverse research has been conducted to develop antibody therapeutics by adding bispecific or multispecific properties, enabling the monospecific antibodies to bind specifically to two or more antigen proteins.
[0004] Bispecific antibodies are dual-functional antibodies that simultaneously interact with two different antigens. An effective strategy for generating bispecific antibodies is based on the approach of mutating the CH3 amino acid residue to form a knob on one half of the antibody and a hole on the other half. This knob-into-hole (KiH) technique has been reported to generate approximately 80% heterodimers (Ridgway, Presta et al. 1996).
[0005] However, there is still a need for improvement / modification to enhance the bispecificity of currently developed dual-specific antibodies.
[0006] Under this technical background, the inventors of the present application confirmed that the bispecificity of antibodies can be enhanced through CH3 domain engineering by producing a heterodimer comprising a pair of CH3 domain variants including amino acid substitutions at specific positions in addition to the conventional Knob-into-Holes (KiH) technology, and completed the present invention.
[0007]
[0008] Summary of the invention
[0009] An object of the present invention is to provide a heterodimer comprising a pair of CH3 domain variants.
[0010] The purpose of the present invention is to provide a fusion protein comprising the above heterodimer.
[0011] An object of the present invention is to provide a bispecific antibody comprising a heterodimer comprising a pair of CH3 domain variants.
[0012] In order to achieve the above purpose, the present invention is a heterodimer comprising a first heavy chain CH3 domain and a second heavy chain CH3 domain,
[0013] The first heavy chain CH3 domain or the second heavy chain CH3 domain comprises one or more amino acid substitutions (according to the EU index) at a position selected from the group consisting of:
[0014] (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R;
[0015] (2) The amino acid at position D399 is substituted with W, F, Y or H;
[0016] (3) amino acid at position K360, K370 or K439 is substituted with Q, N, E or D; and
[0017] (3) Substitution of the amino acid at position K409 with A, V, T or S;
[0018] A heterodimer is provided in which the first heavy chain CH3 domain and the second heavy chain CH3 domain combine to form a dimer.
[0019] The present invention also provides a fusion protein comprising the heterodimer.
[0020] The present invention relates to a bispecific antibody comprising a first arm binding to a first antigen comprising VH1-CHa-Fc1 and VL1-CLb; and a second arm binding to a second antigen comprising VH2-CH1-Fc2 and VL2-CL.
[0021] The above VH1 and VH2 are heavy chain variable regions each including the same or different antigen binding regions,
[0022] The above VL1 and VL2 are light chain variable regions each containing the same or different antigen binding regions,
[0023] The above CHa comprises i) an IgG heavy chain constant region or an IgD heavy chain constant region CH1, and an IgG heavy chain constant region CH2 or CH3,
[0024] The above CLb comprises at least one selected from the group consisting of i) CL1 comprising an IgG light chain constant region λ or κ and IgG heavy chain constant regions CH1, CH2, CH3,
[0025] The above CH1 is the IgG heavy chain constant region CH1, and CL is the IgG light chain constant region CL,
[0026] F of the above first cancer c1 and F of the second cancer c2 combine to form a heavy chain constant region dimer,
[0027] CH3 of the above CHa, F of the first arm c1 or F of the second cancer c2A bispecific antibody comprising a heterodimer comprising a first heavy chain CH3 domain and a second heavy chain CH3 domain comprising one or more amino acid substitutions (according to the EU index) at positions selected from the group consisting of:
[0028] (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R;
[0029] (2) The amino acid at position D399 is substituted with W, F, Y or H;
[0030] (3) amino acid at position K360, K370 or K439 is substituted with Q, N, E or D; and
[0031] (3) The amino acid at position K409 is substituted with A, V, T, or S.
[0032]
[0033] Figure 1 illustrates the structure of a bispecific antibody comprising a heterodimer comprising a mutation according to the present invention.
[0034] Figure 2 shows the overall structure and mutation target region of the CH3 domain of the dual specific antibody.
[0035] Figure 3 is a diagram of the mutation candidate region.
[0036] Figure 4 shows the results of expression pattern analysis using non-reducing SDS-PAGE of the filtered supernatant. Figures 5a to 5f show the results of non-reducing and reducing SDS-PAGE analysis of the products of the first purification of dual-specific antibody candidates.
[0037] Figure 6 shows the results of a single antigen binding ELISA including ErbB2 and VEGF binding regions.
[0038] Figure 7 shows the results of a dual antigen binding ELISA including ErbB2 and VEGF binding regions.
[0039] Figure 8 shows the results of quantitative analysis of the binding strength of dual antibodies and ErbB2 expressed on the surface of JIMT-1 cells using FACS.
[0040]
[0041] Detailed description and specific implementation examples of the invention
[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.
[0043] In one aspect, the present invention is a heterodimer comprising a first heavy chain CH3 domain and a second heavy chain CH3 domain,
[0044] The first heavy chain CH3 domain or the second heavy chain CH3 domain comprises one or more amino acid substitutions (according to the EU index) at a position selected from the group consisting of:
[0045] (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R;
[0046] (2) The amino acid at position D399 is substituted with W, F, Y or H;
[0047] (3) amino acid at position K360, K370 or K439 is substituted with Q, N, E or D; and
[0048] (3) Substitution of the amino acid at position K409 with A, V, T or S;
[0049] It relates to a heterodimer in which the first heavy chain CH3 domain and the second heavy chain CH3 domain combine to form a dimer.
[0050] The above heterodimer is based on a first heavy chain CH3 domain and a second heavy chain CH3 domain, each of which may be considered a monomer, and "monomer" may mean half of the heterodimer. The above heterodimer may be formed by assembly of monomers. The heterodimer may be formed by inducing amino acid mutations in each of the above monomers and assembling the mutated monomers.
[0051] Specifically, it can form knob-into-holes (KiH) by including mutations that create steric effects that are favorable for heterodimer formation and unfavorable for homodimer formation. The heterodimer forms a pair of mutated CH3 domains, specifically, including mutations, for example, amino acid substitutions, in each of the first heavy chain CH3 domain and the second heavy chain CH3 domain of each monomer.
[0052] With respect to Knob-into-Holes (KiH), a knob can be formed by including a mutation, for example, an amino acid substitution, in the first heavy chain CH3 domain, and a hole can be formed by including a mutation, for example, an amino acid substitution, in the second heavy chain CH3 domain, thereby forming Knob-into-Holes (KiH).
[0053] Accordingly, the first heavy chain CH3 domain or the second heavy chain CH3 domain comprises one or more amino acid substitutions (according to the EU index) at positions selected from the group consisting of:
[0054] (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R;
[0055] (2) The amino acid at position D399 is substituted with W, F, Y or H;
[0056] (3) Substitution of the amino acid at position K360, K370 or K439 with Q, N, E or D;
[0057] (3) Substitution of the amino acid at position K409 with A, V, T or S;
[0058] The first heavy chain CH3 domain and the second heavy chain CH3 domain combine to form a dimer.
[0059] In another aspect, the present invention relates to a bispecific antibody comprising a first arm binding to a first antigen comprising VH1-CHa-Fc1 and VL1-CLb; and a second arm binding to a second antigen comprising VH2-CH1-Fc2 and VL2-CL.
[0060] The above VH1 and VH2 are heavy chain variable regions each including the same or different antigen binding regions,
[0061] The above VL1 and VL2 are light chain variable regions each containing the same or different antigen binding regions,
[0062] The above CHa comprises i) an IgG heavy chain constant region or an IgD heavy chain constant region CH1, and an IgG heavy chain constant region CH2 or CH3,
[0063] The above CLb comprises at least one selected from the group consisting of i) CL1 comprising an IgG light chain constant region λ or κ and IgG heavy chain constant regions CH1, CH2, CH3,
[0064] The above CH1 is the IgG heavy chain constant region CH1, and CL is the IgG light chain constant region CL,
[0065] F of the above first cancer c1 and F of the second cancer c2 combine to form a heavy chain constant region dimer,
[0066] CH3 of the above CHa, F of the first arm c1 or F of the second cancer c2A bispecific antibody comprising a heterodimer comprising a first heavy chain CH3 domain and a second heavy chain CH3 domain comprising one or more amino acid substitutions (according to the EU index) at positions selected from the group consisting of:
[0067] (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R;
[0068] (2) The amino acid at position D399 is substituted with W, F, Y or H;
[0069] (3) amino acid at position K360, K370 or K439 is substituted with Q, N, E or D; and
[0070] (3) The amino acid at position K409 is substituted with A, V, T, or S.
[0071] The present invention is a new form different from the dual-specific antibody described in the prior Korean Patent Publication No. 2022-0095163, and can improve the yield of heterodimers compared to existing dual-specific antibodies by minimizing mispairing by introducing different mutation pairs into the CH3 domains that overlap in Fc and Fab.
[0072] The above heterodimer is based on a first heavy chain CH3 domain and a second heavy chain CH3 domain, each of which may be considered a monomer, and "monomer" may mean half of the heterodimer. The above heterodimer may be formed by assembly of monomers. The heterodimer may be formed by inducing amino acid mutations in each of the above monomers and assembling the mutated monomers.
[0073] Specifically, it can form knob-into-holes (KiH) by including mutations that create steric effects that are favorable for heterodimer formation and unfavorable for homodimer formation. The heterodimer forms a pair of mutated CH3 domains, specifically, including mutations, for example, amino acid substitutions, in each of the first heavy chain CH3 domain and the second heavy chain CH3 domain of each monomer.
[0074] With respect to Knob-into-Holes (KiH), a knob can be formed by including a mutation, for example, an amino acid substitution, in the first heavy chain CH3 domain, and a hole can be formed by including a mutation, for example, an amino acid substitution, in the second heavy chain CH3 domain, thereby forming Knob-into-Holes (KiH).
[0075] Accordingly, the first heavy chain CH3 domain or the second heavy chain CH3 domain comprises one or more amino acid substitutions (according to the EU index) at positions selected from the group consisting of:
[0076] (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R;
[0077] (2) The amino acid at position D399 is substituted with W, F, Y or H;
[0078] (3) Substitution of the amino acid at position K360, K370 or K439 with Q, N, E or D;
[0079] (3) Substitution of the amino acid at position K409 with A, V, T or S;
[0080] The first heavy chain CH3 domain and the second heavy chain CH3 domain combine to form a dimer.
[0081] The antibody binding to the above heterodimer may be of any type, including but not limited to Fab, Fab', F(ab')2, vH, vL, Fv, scFv, scFv2, scFab or dAb.
[0082] “Bispecific” or “bispecific” refers to the property of a binding protein to specifically bind to two different targets and modulate the activity of the targets, for example by conjugation of a monoclonal antibody or fragment thereof that specifically binds to each target, has two distinct antigen-binding arms (specific for two targets), and is monovalent for each antigen it binds.
[0083] The above VH1 and VH2 are heavy chain variable regions each including the same or different antigen-binding regions. The above VL1 and VL2 are light chain variable regions each including the same or different antigen-binding regions.
[0084] "Polypeptide" refers to any polymeric chain of amino acids. The terms "peptide" and "protein" may be used interchangeably with the term "polypeptide," which also refers to a polymeric chain of amino acids. "Polypeptide" includes natural or synthetic proteins, protein fragments, and polypeptide analogs of protein sequences. Polypeptides may be monomers or polymers.
[0085] In the context of an interaction between an antibody, polypeptide, protein, or peptide, the terms "specific binding" or "binding specifically" mean that the interaction is contingent on the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species. For example, antibodies generally recognize and bind to a specific protein structure rather than the protein itself. If an antibody is specific for epitope "A," then in a reaction involving labeled "A" and the antibody, the presence of a molecule containing epitope A (or free, unlabeled A) will decrease the amount of labeled A bound to the antibody.
[0086] An antibody is any immunoglobulin (Ig) molecule composed of four polypeptide chains, namely two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivative of such an Ig molecule having the essential epitope binding characteristics. Specific examples of such mutants, variants, or derivatives are discussed below, but are not limited thereto.
[0087] A "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., identical except for possible naturally occurring mutations that may be present in trace amounts in individual antibodies within the population. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to conventional (polyclonal) antibody preparations, which typically contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
[0088] An "epitope" is a protein determinant to which an antibody can specifically bind. Epitopes typically consist of chemically active surface molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished by the fact that binding to the former is lost in the presence of denaturing solvents, while binding to the latter is not.
[0089] Non-human (e.g., murine) antibodies in the form of "humanized" antibodies are chimeric antibodies that contain minimal sequence derived from a non-human immunoglobulin. In most cases, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from the hypervariable region of the recipient antibody are replaced with residues from the hypervariable region of a non-human species (donor antibody) that retains the desired specificity, affinity, and ability, such as mouse, rat, rabbit, or non-human primate.
[0090] “Human antibody” means a molecule derived from human immunoglobulin, in which the entire amino acid sequence constituting the antibody, including the complementarity determining region and structural region, is composed of human immunoglobulin.
[0091] In a complete antibody, each heavy chain consists of a heavy chain variable region (designated HCVR or VH) and a heavy chain constant region. The heavy chain constant region consists of three domains, CH1, CH2, and CH3. Each light chain consists of a light chain variable region and a light chain constant region. The light chain constant region consists of a single domain, CL. The VH and VL regions can be further divided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). "Variable region" refers to the light and heavy chain portions of an antibody molecule that comprise the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and the framework regions (FRs). VH refers to the variable region of the heavy chain. VL refers to the variable region of the light chain.
[0092] "Complementarity determining regions" (CDRs; i.e., CDR1, CDR2, and CDR3) refer to the amino acid residues of an antibody variable region that are necessary for antigen binding. Each variable region typically has three CDR regions, identified as CDR1, CDR2, and CDR3. A "framework region" (FR) is a variable region residue other than the CDR residues. Each variable region typically has four FRs, identified as FR1, FR2, FR3, and FR4. These are arranged in the following order from amino terminus to carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0093] The Fab fragment has a single antigen-binding site, consisting of the variable regions of the light and heavy chains, the constant region of the light chain, and the first constant region (CH1) of the heavy chain. The Fab' fragment differs from the Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the CH1 domain of the heavy chain. F(ab')2 is produced when the cysteine residues in the hinge region of Fab' form a disulfide bond. Fv is the smallest antibody fragment that contains only the heavy and light chain variable regions. A two-chain Fv has a heavy chain variable region and a light chain variable region linked non-covalently, while a single-chain Fv (single-chain Fv, scFv) has a heavy chain variable region and a light chain variable region linked covalently, usually via a peptide linker, or directly at the C-terminus, so that it can form a dimer-like structure like a two-chain Fv. These antibody fragments can be obtained using proteolytic enzymes (for example, restriction digestion of whole antibodies with papain yields Fab fragments, and digestion with pepsin yields F(ab')2 fragments), or they can be produced using genetic recombination techniques.
[0094] An antibody fragment comprising an “antigen binding portion” which is one or more antibody fragments having a specific binding ability to an antigen, and which can specifically bind to different antigens, and thus may be bispecific, bispecific, or multispecific. In the present invention, the antigen binding portion is contained in the heavy chain variable region of VH1 or VH2 and the light chain variable region of VL1 or VL2, each of which comprises the same or different antigen binding portions.
[0095] According to the present invention, the IgG-like structure does not significantly deviate from the IgG structure. Structures that significantly damage the IgG structure are likely to significantly increase protein instability.
[0096] Furthermore, the frequency of mispairing was drastically reduced by introducing an additional constant region of the immunoglobulin structure into the light chain mispairing region. By introducing the known constant region domain of the heavy chain into one of the two Fab arms, light chain mispairing was prevented.
[0097] The above-mentioned dual-specific antibody has no structural modification in the left arm (second arm) of the two Fab portions that bind to the target, additionally introduces an Ig constant domain (CH3) in the right arm (first arm), introduces various types of CH1 instead of IgG1 CH1 and other than IgG1 CH1, and the heterodimer configuration of the heavy chain can introduce a knob-in-hole structure.
[0098] The above CHa may include i) an IgG heavy chain constant region or an IgD heavy chain constant region CH1, and an IgG heavy chain constant region CH2 or CH3.
[0099] For example, CHa may comprise, in order from N-terminus to C-terminus, a heavy chain constant region CH1 derived from IgG1, IgG2, IgG3, IgG4, IgD, or IgM, and a heavy chain constant region CH3 derived from IgG1, IgG2, IgG3, or IgG4 in the first arm. For example, CHa may comprise, in order from N-terminus to C-terminus, a heavy chain constant region CH1 derived from IgG1, IgG2, IgG3, IgG4, IgD, or IgM in the first arm.
[0100] The above CLb comprises at least one selected from the group consisting of i) CL1 comprising an IgG light chain constant region λ or κ and IgG heavy chain constant regions CH1, CH2, CH3.
[0101] The CLb may include at least one selected from the group consisting of CL1 comprising a light chain constant region λ or κ derived from IgG1, IgG2, IgG3, IgG4, IgD or IgM and heavy chain constant regions CH1, CH2, CH3 derived from IgG1, IgG2, IgG3, IgG4. For example, the CLb may include CL1 comprising a light chain constant region λ or κ derived from IgG1, IgG2, IgG3, IgG4, IgD or IgM and a heavy chain constant region CH3 derived from IgG1, IgG2, IgG3, IgG4 in order from N-terminus to C-terminus among the first arm. For example, the CLb may include CL1 comprising a CH3 derived from IgG1, IgG2, IgG3, IgG4 and a light chain constant region λ or κ derived from IgG1, IgG2, IgG3, IgG4, IgD or IgM in order from N-terminus to C-terminus among the first arm.
[0102] The CH1 above is an IgG heavy chain constant region CH1, and the CL is an IgG light chain constant region CL. Each of the CH1 and CL may be derived from IgG1, IgG2, IgG3, IgG4, or IgD. The CH1 and CL may have a structure similar to a Fab fragment through non-covalent interaction.
[0103] The term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain that can be generated by papain digestion of an intact antibody. The Fc region may be a native sequence Fc region or a variant Fc region. The Fc region of an immunoglobulin typically comprises two constant domains, a CH2 domain and a CH3 domain, and optionally a CH4 domain.
[0104] In one embodiment, the CHa and CLb may each comprise CH3. Specifically, the CHa and CLb may each comprise CH3 derived from IgG1, IgG2, IgG3, or IgG4. The CHa and CLb may form a dimer through covalent or non-covalent interaction.
[0105] In some cases, the CH3 domain and the CH1 domain may be connected by a linker. The linker may be a peptide linker and may comprise about 5-25 amino acid residues, or more specifically, about 5-10 amino acid residues. For example, hydrophilic amino acids such as glycine and / or serine may be included, but are not limited thereto.
[0106] Specifically, the linker may comprise, for example, a glycine linker (G, Gly)p (p is 1 to 10), a GS linker (GnS)m (n, m are each 1 to 10) to impart structural flexibility. Specifically, the linker may comprise GGGGS or (GGGGS)2, or a glycine of 5-10 aa in which p is 5-10 in (G, Gly)p.
[0107] The first and second arms may be connected via a hinge. The first and second arms may be connected via a hinge formed by including one or more sequences selected from the group consisting of:
[0108] DKTHTCPPCP;
[0109] EPKSSDKTHTCPPCP; and
[0110] ESKYGPPCPPCP.
[0111] F of the above first cancer c1 and F of the second cancer c2Each of them comprises CH2 and CH3 monomers of the heavy chain constant region. The monomer refers to one domain of a dimer formed by two constant domains CH2-CH3 having the same amino acid sequence of the heavy chain constant region Fc. The F of the first arm c1 and F of the second cancer c2 combine to form a heavy chain constant region dimer.
[0112] The above dimer may include a homodimer formed by binding between constant domain CH3s having the same amino acid sequence or a heterodimer formed by binding between constant domain CH3s having different amino acid sequences.
[0113] "Amino acid substitution" or "substitution" may refer to the replacement of an amino acid at a specific position within the amino acid sequence of a CH3 domain. In particular, in some embodiments, the substitution comprises an amino acid that does not occur naturally at the specific position or has a sequence different from the naturally occurring amino acid sequence.
[0114] The above CH3 domain is derived from an immunoglobulin (Ig) domain, which is a region of an immunoglobulin having a tertiary structure, and may be derived from an immunoglobulin selected from the group consisting of IgG, IgM, IgA, IgD, and IgE, but may specifically be derived from IgG. The IgG may be human IgG.
[0115] With respect to human IgG, the “CH” domains are as follows: “CH1” refers to positions 118 to 220 according to the EU index, “CH2” refers to positions 237 to 340 according to the EU index, and “CH3” refers to positions 341 to 447 according to the EU index.
[0116] The sequence of the first domain of the CH3 domain at positions 341 to 447 according to the EU index is as follows:
[0117] GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 1).
[0118] The sequence of the second domain of the CH3 domain at positions 341 to 447 according to the EU index is as follows:
[0119] GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 2).
[0120] Below, the CH3 domain at positions 341 to 447 of IgG is described based on the EU index.
[0121] Specifically, the amino acid at position Q347, E356 or E357 in the first heavy chain CH3 domain may be substituted with K or R, or the amino acid at position D399 may be substituted with W, F, Y or H.
[0122] In one embodiment, the first heavy chain CH3 domain may comprise one or more selected from the group consisting of Q347K, Q347R, E357K, E357R, E356K, E356R, D399W, D399F, D399Y, and D399H. Specifically, the first heavy chain CH3 domain may comprise one or more selected from the group consisting of Q347K, E357K, E356K, D399W, D399F, D399Y, and D399H.
[0123] Additionally, the amino acid at position K360, K370 or K439 in the second heavy chain CH3 domain may be substituted with Q, N, E or D, or the amino acid at position K409 may be substituted with A, V, T or S.
[0124] In one embodiment, the second heavy chain CH3 domain may comprise one or more selected from the group consisting of K360Q, K360N, K360E, K360D, K370E, K370D, K370N, K370Q, K439E, K439D, K439N, K439Q, K409A, K409V, K409T, and K409S. Specifically, the second heavy chain CH3 domain may comprise one or more selected from the group consisting of K360Q, K360N, K360E, K360D, K370E, K439E, K439D, K409A, K409T, and K409S.
[0125] In one embodiment, the substitution may include one or more, two or more, three or more, or all four of the following:
[0126] Containing Q347K or Q347R in the first heavy chain CH3 domain, and K360Q, K360N, K360E or K360D in the second heavy chain CH3 domain;
[0127] Containing E357K or E357R among the first heavy chain CH3 domains, and containing K370Q, K370N, K370E or K370D among the second heavy chain CH3 domains;
[0128] comprising E356K or E356R among the first heavy chain CH3 domains and comprising K439Q, K439N, K439E or K439D among the second heavy chain CH3 domains; and
[0129] Among the first heavy chain CH3 domains, comprising D399W, D399F, D399Y or D399H, and among the second heavy chain CH3 domains, comprising K409A, K409T, K409V or K409S.
[0130] In one embodiment, the substitution may include one or more, two or more, three or more, or all four of the following:
[0131] Contains Q347K in the first heavy chain CH3 domain, and comprises K360Q, K360N, K360E, or K360D in the second heavy chain CH3 domain;
[0132] Contains E357K in the first heavy chain CH3 domain and K370E in the second heavy chain CH3 domain;
[0133] Containing E356K in the first heavy chain CH3 domain and K439E or K439Q in the second heavy chain CH3 domain;
[0134] Containing D399W, D399F, D399Y or D399H in the first heavy chain CH3 domain and K409A, K409T or K409S in the second heavy chain CH3 domain.
[0135] In a specific embodiment according to the present invention, the first heavy chain CH3 domain may include at least one selected from the group consisting of Q347K, E357K, E356K, D399W, D399F, D399Y and D399H, and the second heavy chain CH3 domain may include at least one selected from the group consisting of K360Q, K360N, K360E, K360D, K370E, K439E, K439D, K409A, K409T and K409S.
[0136] In specific embodiments according to the present invention, one or more substitution combinations selected from the following groups may be included.
[0137] Contains Q347K in the first heavy chain CH3 domain, K360Q in the second heavy chain CH3 domain, and E357K in the first heavy chain CH3 domain, and K370E in the second heavy chain CH3 domain;
[0138] Contains Q347K in the first heavy chain CH3 domain, K360Q in the second heavy chain CH3 domain, and E356K in the first heavy chain CH3 domain, and K439E in the second heavy chain CH3 domain;
[0139] Contains E357K in the first heavy chain CH3 domain, K370E in the second heavy chain CH3 domain, and E356K in the first heavy chain CH3 domain and K439E in the second heavy chain CH3 domain;
[0140] Contains Q347K in the first heavy chain CH3 domain, K360Q in the second heavy chain CH3 domain, and D399W in the first heavy chain CH3 domain and K409A in the second heavy chain CH3 domain;
[0141] Contains E357K in the first heavy chain CH3 domain, K370E in the second heavy chain CH3 domain, and D399W in the first heavy chain CH3 domain, and K409A in the second heavy chain CH3 domain;
[0142] Contains E356K in the first heavy chain CH3 domain, K439E in the second heavy chain CH3 domain, and D399W in the first heavy chain CH3 domain and K409A in the second heavy chain CH3 domain;
[0143] Containing Q347K in the first heavy chain CH3 domain, K360Q in the second heavy chain CH3 domain, E357K in the first heavy chain CH3 domain, K370E in the second heavy chain CH3 domain, and E356K in the first heavy chain CH3 domain, K439E in the second heavy chain CH3 domain;
[0144] Contains E357K in the first heavy chain CH3 domain, K370E in the second heavy chain CH3 domain, D399W in the first heavy chain CH3 domain, K409A in the second heavy chain CH3 domain, and E356K in the first heavy chain CH3 domain, and K439E in the second heavy chain CH3 domain;
[0145] Contains Q347K in the first heavy chain CH3 domain, K360Q in the second heavy chain CH3 domain, D399W in the first heavy chain CH3 domain, K409A in the second heavy chain CH3 domain and E356K in the first heavy chain CH3 domain, and K439E in the second heavy chain CH3 domain; and
[0146] Contains Q347K in the first heavy chain CH3 domain, K360Q in the second heavy chain CH3 domain, E357K in the first heavy chain CH3 domain, K370E in the second heavy chain CH3 domain, D399W in the first heavy chain CH3 domain, K409A in the second heavy chain CH3 domain and E356K in the first heavy chain CH3 domain, and K439E in the second heavy chain CH3 domain.
[0147] In some cases, the first heavy chain CH3 domain or the second heavy chain CH3 domain may additionally include one or more selected from the group consisting of Y349C, S354C, T366S, T366W, L368A, and Y407V.
[0148] In one embodiment, one of the first heavy chain CH3 domain or the second heavy chain CH3 domain may further comprise one or more selected from the group consisting of Y349C, S354C, T366S, T366W, L368A, and Y407V, and the other of the first heavy chain CH3 domain or the second heavy chain CH3 domain may further comprise one or more selected from the group consisting of S354C, Y349C, T366W, T366S, L368A, and Y407V.
[0149] Specifically, it may include residue mutations according to the present invention.
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165] From another perspective, the present invention relates to a fusion protein comprising the heterodimer.
[0166] The heterodimer may be bound to one end of a polypeptide or protein, such as, for example, a peptide, a cytokine such as IL-2, IL-10, IL-12, GCSF, GM-CSF, a chemokine such as RANTES, CXCL9, CXCL10, CXCL12, a hormone, an immune checkpoint protein such as CTLA-4, TNFR1, TNFRII, TNFSF, TNFRSF, or a blood factor.
[0167] The heterodimer may be linked to the N-terminus or C-terminus of a polypeptide or protein. In some cases, the heterodimer may be linked to the polypeptide or protein by a linker. The linker may be a peptide linker and may include about 5-25 aa residues, or more specifically, about 5-10 aa residues. For example, hydrophilic amino acids such as glycine and / or serine may be included, but are not limited thereto.
[0168]
[0169] In the bispecific antibody format according to the present invention, the heavy chain and light chain of the first arm that binds to the first antigen are configured as follows. The heavy chain of the first arm is configured in the order of VH-CH3a-Linker-CH1a-Hinge-CH2-CH3b. The CH1a domain may use an IgG1 CH1 domain. The CH3a domain may include a mutation in Hole and a mutation for forming a disulfide bond with CH3c of the light chain. The CH3b domain may include a mutation for forming a disulfide bond. In some cases, an elbow sequence AS may be added between the VH region and the CH3a region.
[0170] Considering mutations having biologically equivalent activity, it is understood that substitutions according to the present invention also include substitutions with sequences that exhibit substantial identity with the described sequence.
[0171] Substantial identity means a sequence that exhibits at least 61% homology, more preferably 70% homology, even more preferably 80% homology, and most preferably 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homology when the sequence of the present invention and any other sequence are aligned to the greatest extent possible and the aligned sequences are analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) is accessible from NBCI, etc., and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn, and tblastx on the Internet. BLAST is accessible at www.ncbi.nlm.nih.gov / BLAST / . How to compare sequence homology using this program can be found at www.ncbi.nlm.nih.gov / BLAST / blast_ help.html.
[0172]
[0173] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples. Therefore, the actual scope of the present invention is defined by the appended claims and their equivalents.
[0174]
[0175] Example 1. Design and Engineering of S-DUAL 2G antibody
[0176]
[0177] 1.1. Introduction of CH3 domain amino acid residue variants
[0178] The composition of a bispecific antibody format that simultaneously binds to a first antigen and a second antigen is as follows. The bispecific antibody format is formed by assembling a total of four polypeptides, namely, two heavy chains (H) and two light chains (L). The composition of the heavy chain and light chain of the first arm that binds to the first antigen is as follows. The composition of the heavy chain is composed of VH-CH3D-CH1a-Hinge-CH2-CH3B. Here, CH3B and CH3D include the sequence of the IgG1 CH3 domain, and the CH1a region may include the sequence of the IgG1 CH1 domain. Among the domains that constitute the heavy chain, the IgG1 CH3B and CH3D domains include mutations of Knob (T366W) or Hole (T366S / L368A / Y407V). IgG1 CH3B and CH3D domains can also contain mutations to create cysteine to form disulfide bonds between domains, i.e. Knob(S354C / T366W) or Knob(Y349C / T366W) or Hole(S354C / T366S / L368A / Y407V) or Hole(Y349C / T366S / L368A / Y407V). The IgG1 CH3 mutation candidates were derived by screening amino acid residues that play a major role in the binding between the CH3A-CH3B domains that constitute the heavy chain constant region in the 'protein interaction analysis' panel of Bioluminate® (Schrodinger, LLC), and applying replaceable mutant amino acids that do not cause clashes with the side chain structure of neighboring amino acid residues. Based on the above candidates, four amino acid residue mutation pairs with high interaction energy values between heterodimers (CH3A-CH3B) but low interaction energy values between homodimers (CH3A-CH3A, CH3B-CH3B) were selected through structural modeling. Then, single, double, or triple amino acid residue mutations were introduced into the bispecific antibody in the CH3 domain pairs of the heavy chain constant region.
[0179] The light chain of the first arm that binds to the first antigen is composed of VL-CH3C-CLb. Here, CH3C represents the IgG1 CH3 domain, which contains mutations of Knob (T366W) or Hole (T366S / L368A / Y407V). The IgG1 CH3 domain may also contain mutations to create cysteine for disulfide bonds, i.e., Knob (S354C / T366W) or Knob (Y349C / T366W) or Hole (S354C / T366S / L368A / Y407V) or Hole (Y349C / T366S / L368A / Y407V). The heavy chain and light chain compositions of the second arm that binds to the second antigen are as follows. The heavy chain is composed of VH-CH1-Hinge-CH2-CH3A. The IgG1 CH3A domain contains mutations of Knob (T366W) or Hole (T366S / L368A / Y407V). The IgG1 CH3A domain may also contain mutations to generate cysteine for disulfide bond, i.e., Knob (S354C / T366W) or Knob (Y349C / T366W) or Hole (S354C / T366S / L368A / Y407V) or Hole (Y349C / T366S / L368A / Y407V). The light chain of the second arm is composed of VL-CLb. Based on the above bispecific antibody format, we attempted to introduce additional IgG1 CH3 mutations to improve the yield of heterodimer formation. The IgG1 CH3 mutation candidate group was formed by introducing a single combination of four amino acid residue mutations into the CH3B domain of the heavy chain of the first arm that binds the first antigen, VH-CH3D-CH1a-Hinge-CH2-CH3B, and the CH3C domain of the CH3D domain and light chain, VL-CH3C-CLb.
[0180]
[0181] 1.2 Design by anti-VEGF x anti-HER2 bispecific antibody
[0182] The first antigen was determined to be the HER2 protein, and the heavy chain variable region amino acid sequence of Trastuzumab, which binds to HER2, and the light chain variable region amino acid sequence were used for the VH or VL of the bispecific antibody format. The second antigen was determined to be the VEGF-A target, and the heavy chain variable region amino acid sequence of Bevacizumab and the light chain variable region amino acid sequence were used for the VH or VL of the bispecific antibody format. Amino acid sequence information was obtained through https: / go.drugbank.com / .
[0183]
[0184]
[0185]
[0186] The specific composition of each candidate is as shown in Table 3.
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217] Example 2. Production of bispecific antibodies containing CH3 domain variants
[0218]
[0219] A vector plasmid containing the coding genes for the heavy chain region and light chain region (Q-SBL) of the first arm and a vector plasmid containing the coding genes for the heavy chain region and light chain region of the second arm were constructed. To express the second arm, the genes encoding the heavy and light chains were inserted into one vector plasmid. The promoter used was CMV, and the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was inserted after the coding gene to design an increased expression level during transient expression.
[0220] Co-transfection was performed with a vector plasmid containing the coding gene of the first arm and a vector plasmid containing the coding gene of the second arm into ExpiCHO-S animal cells (Thermo Fisher, A29127). At this time, the ratio of the vector plasmid for expressing the first arm and the vector plasmid for expressing the second arm was 1:1 (Q-SBL). For transfection, the ExpiFectamine CHO Transfection Kit (Thermo Fisher, A29130) was used according to the manufacturer's manual. 13 days after transfection, the supernatant was obtained through centrifugation (10,000 rpm, 15 mins) to obtain a dual-specific antibody, and the supernatant was filtered through a 0.22 μm filter paper to remove residual cell debris.
[0221]
[0222] Example 3. Expression of a dual-specific antibody comprising a CH3 domain variant.
[0223]
[0224] The expression yield of the bispecific antibody containing the CH3 domain variant was measured on an Octet instrument [Table 4]. Using a Protein A biosensor (Sartorius 18-5010), a calibration curve was obtained using an IgG1 type standard substance, and the concentration of the bispecific antibody in the CHO cell culture supernatant (harvest cell culture fluid, HCCF) was determined using the calibration curve.
[0225]
[0226] Example 4. Purification of a bispecific antibody containing a CH3 domain mutant.
[0227]
[0228] In order to study and analyze the bispecific antibodies to which the mutant candidates of the CH3 domain of the present invention were applied, the candidates were expressed and the culture medium obtained was subjected to the first purification of the bispecific antibodies using a MabSelect Sure (Cytiva) column, a Protein A affinity chromatography. The bispecific antibody substances obtained in the first purification process step were identified by performing non-reducing SDS-PAGE using a 3-8% Tris-acetate gel and Tris-acetate buffer. In addition, reducing SDS-PAGE using a 4-12% Bis-Tris gel and Bis-Tris buffer was performed to confirm the presence of fragments other than those derived from the bispecific antibodies.
[0229] Specifically, after equilibrating the MabSelect Sure column with a 50 mM Tris-HCl (pH 7.0) buffer solution (equilibration buffer solution), the bispecific antibody culture solution including the mutants filtered through a 0.22 μm filter paper was loaded onto the column. Proteins that did not bind to the column were washed away using the above equilibration buffer solution, and impurities nonspecifically bound to the column were removed sequentially using an equilibration buffer solution containing 0.5 M sodium chloride and a 20 mM Bis-Tris (pH 5.8) buffer solution. Thereafter, the bispecific antibody specifically binding to the column was eluted by flowing a 0.2 M Glycine-HCl (pH 3.2) buffer solution. The eluted sample was neutralized to pH 5.0 using a 1.0 M Tris solution and then filtered through a 0.22 μm filter paper.
[0230] The following purification process was performed using a Capto SP (Cytiva) column, a cation exchange chromatography among ion exchange chromatography, and the details are as follows. After stabilizing the Capto SP column with a 50 mM Bis-Tris (pH 6.0) buffer solution, a bispecific antibody sample titrated to pH 6.0 was applied, and impurities that did not bind to the column were washed with the same buffer solution. The bispecific antibody bound to the column was eluted using sodium chloride ranging from 0.1 M to 1.0 M.
[0231] The final purification step involved hydrophobic interaction chromatography to remove high molecular weight (HMW) and low molecular weight (LMW) impurities from the bispecific antibody sample that had undergone secondary purification. A butyl-based sepharose column was used in this process, and the sample was prepared by replacing the salt concentration in the bispecific antibody purified by ion exchange chromatography with a high-concentration salt buffer solution so that the salt concentration in the purified product ranged from 1.0 M to 1.5 M. After equilibrating the column with a 50 mM Bis-Tris (pH 6.0) buffer solution having the same salt concentration as the applied sample, the prepared sample was loaded. The bound bispecific antibody was eluted in a gradient manner for 30 CV with 50 mM Bis-Tris (pH 6.0) without salt. The final purified product of the eluted bispecific antibody was concentrated to a concentration of 1 to 2 mg / mL using a 50 kDa molecular-weight cut-off ultrafiltration tube and then replaced with a suitable buffer solution depending on the analysis conditions.
[0232]
[0233] Example 5. Purity analysis using size exclusion high-pressure chromatography (SEC-HPLC)
[0234]
[0235] Size exclusion high pressure chromatography was performed to confirm the aggregation and heterodimer purity of the bispecific antibody candidates. Approximately 50 μg of the purified product passing through the protein A resin was passed through a TSKGel G3000SWXL (Tosoh) column at a flow rate of 0.5 mL / min using a Waters Alliance 2695 HPLC and 2489 UV / Vis detector system in a mobile phase of 250 mM potassium phosphate, 200 mM potassium chloride, pH 7.2, and the UV absorbance was measured at 280 nm. System suitability was confirmed using the Bio-Rad Gel filtration standard (151-1901), and after analysis, the data were integrated using the manufacturer's Empower 3.0 software to determine the purity as a percent area ratio. The SEC-HPLC analysis results are shown in [Table 5] below.
[0236]
[0237] Example 6. CE-SDS analysis
[0238]
[0239] For purity analysis of dual-specific antibody candidates under non-reducing or reducing conditions, sodium dodecyl sulfate capillary electrophoresis (CE-SDS) using PA 800 Plus (Sciex) and the IgG Purity and Heterogeneity Assay Kit (Sciex) was used. For analysis of samples purified using Protein A resin, 50 μL of protein was used at a maximum concentration of 2 mg / mL. For analysis, each sample was mixed with 5 μL of 250 mM iodoacetamide or 14.2 M 2-mercaptoethanol, 2 μL of internal standard, and 45 μL of sodium dodecyl sulfate sample buffer and heated at 70 °C for 10 min (CE-SDS Method 1). Alternatively, 20 μL of protein was used at a maximum concentration of 3.5 mg / mL for analysis of samples purified using Protein A resin. For analysis, each sample was mixed with 5 μL of 250 mM iodoacetamide or 14.2 M 2-mercaptoethanol, 2 μL of internal standard, and 75 μL of sodium dodecyl sulfate sample buffer solution, and then heated at 70 °C for 10 minutes (CE-SDS Method 2).
[0240] After completion of the analysis, the data were analyzed in Karat™ software version 10.3 provided by the manufacturer.
[0241] [Table 6] presents data analyzed on CE-SDS under non-reducing conditions after purification using Protein A resin. The purity of the heterodimer was confirmed by sodium dodecyl capillary electrophoresis (CE-SDS) after purification of the dual-specific antibody candidates using Protein A resin.
[0242]
[0243] Example 7. Single Antigen Binding ELISA
[0244]
[0245] Since the dual antibodies constituting the present invention have multiple targets, both ELISA experiments for single antigen binding and dual antigen binding were performed, and the specific implementation process of the single antigen binding ELISA is as follows. Depending on the target to be confirmed, rhErbB2-his tag, rhVEGF 165 recombinant protein (R&D Systems) was coated on a 96-well immune experiment ELISA plate using 1x PBS pH7.4. At this time, the coating concentration was prepared as 1 μg / ml for rhErbB2-his tag and 0.5 μg / ml for rhVEGF, and 100 μl was treated per well. rhErbB2-his tag, rhVEGF 165 were coated at 37°C for 1 hour, and then washed 5 times with 0.05% PBS-T. To prevent nonspecific binding, 200 μl of 2% BSA was treated per well to perform the blocking process, and the plate was incubated at 37°C for 30 minutes, followed by washing five times with 0.05% PBS-T. The bispecific antibodies described in the present invention were serially diluted (20 to 0.0001 nM) with 2% BSA, added to each well of the recombinant protein-coated plate at 100 μl, incubated at 37°C for 1 hour, and washed five times with 0.05% PBS-T. Next, HRP-conjugated secondary antibodies were diluted using PBS containing 2% BSA (anti-hIgG FC-HRP 1:10,000), added per well at 100 μl, incubated at 37°C for 30 minutes, and washed five times with 0.05% PBS-T. TMB (Bio-Rad), which reacts with HRP of the secondary antibody to develop color, was added at 100 μl per well, and after color development for 5 minutes at room temperature, 100 μl of 1 M H2SO4 was added per well to terminate color development, and then absorbance was measured at a wavelength of 450 nm using a SpectraMax ABS Plus (Molecular Devices) instrument.As a result, the EC50 values for each single antigen binding of the CH3 engineering progress group including the ErbB2 and VEGF binding regions are compared as shown in [Table 7]. [Figure 6] is a graph of the 4-parameter fitting of the binding affinity analysis for each single antigen of ErbB2 and VEGF of the candidate group.
[0246]
[0247] Example 8. Dual Antigen Binding ELISA
[0248]
[0249] The specific implementation process of the dual antigen binding ELISA is as follows. Depending on the target to be confirmed, rhVEGF 165 recombinant protein (R&D Systems) was coated on a 96-well immunoassay ELISA plate using 1x PBS pH 7.4, at a coating concentration of 1 μg / ml (100 μl per well). After coating with rhVEGF 165 for 18 hours at 4°C, the plate was washed five times with 0.05% PBS-T. To prevent nonspecific binding, 200 μl per well of 2% BSA was blocked, incubated at 37°C for 2 hours, and washed five times with 0.05% PBS-T. Dual-specific antibodies serially diluted in 2% BSA at a ratio of 1 / 3 (100–0.0016 nM) based on a maximum concentration of 100 nM and rhErbB2-his (R&D Systems) diluted to 1 μg / ml were mixed 1:1 and incubated at 37°C for 2 h. After washing the microplate five times with 0.05% PBS-T, 100 μl of the previously mixed antibody and rh ErbB2-his samples were added to each well and incubated at 37°C for 2 h, and washed five times with 0.05% PBS-T. Afterwards, 100 μl per well of HRP-conjugated anti-secondary antibody was diluted (anti-his tag-HRP 1:10,000) using PBS containing 2% BSA, incubated at 37°C for 1 hour, and washed five times with 0.05% PBS-T. 100 μl per well of TMB (Bio-Rad) was added, and color development was terminated by adding 100 μl per well of 1 M H2SO4 after 5 minutes of color development at room temperature. The absorbance was measured at a wavelength of 450 nm using a SpectraMax ABS Plus (Molecular Devices) instrument. The EC50 values for dual antigen binding of the CH3 engineering group containing the ErbB2 and VEGF binding regions are compared as shown in [Table 8].[Figure 7] is a graph of 4-parameter fitting of dual antigen binding affinity analysis of ErbB2 and VEGF of the candidate group.
[0250]
[0251] Example 9. Fluorescence-Activated Cell Sorter (FACS)
[0252]
[0253] Fluorescence-activated flow cytometry was performed to confirm whether the antigen binding ability at the cellular level was maintained when the CH3 domain variant according to the present invention was introduced into a bispecific antibody. The specific implementation process of fluorescence-activated flow cytometry is as follows. JIMT-1 cells expressing HER2, the target to be confirmed, were cultured using DMEM medium containing 1% Penicillin-Streptomycin (Gibco, 15140-122) and 10% fetal bovine serum (Gibco, 16140071) at 37°C and 5% CO2 incubator, and the cell density in the 75-T flask was not exceeded 80%. JIMT-1 cells were seeded in a 96-well plate at a density of 2 × 10 5After preparing at a density of 10 cells / well, the dual specific antibody specified in the present invention was prepared at 100 nM using FACS staining buffer (Invitrogen, 00-4222-26), 100 μL was added per well, and reacted with the cells at 4°C for 1 hour. The supernatant was removed through centrifugation (1,000 rpm, 5 minutes), and the cells reacted with the antibodies were washed with 100 μL of FACS buffer to prevent nonspecific binding. The FITC-conjugated secondary antibody was diluted using FACS buffer (Abcam, ab239228, 1:40) and added at 100 μL per well, and reacted with the cells at 4°C for 30 minutes, and the same washing process as above was repeated 3 times. The cells reacted with the antibody were detected by using a fluorescence-activated cell sorter (Satorius, iQue® 3) with a FITC filter to detect the fluorescence emission signal of the exit in the 498 nm region and the emitter in the 475 to 650 nm region. The results are shown in the figure, and the results quantified by the mean fluorescence intensity (MFI) are shown in Table 9 and Figure 8.
[0254]
[0255] Example 9. Analysis of binding kinetics of FcγRIIa, FcγRIIIa, and C1q.
[0256]
[0257] The Fc region (hinge-CH2) of IgG1 interacts with the Fcγ receptor (FcγR) and complement protein (C1q, Complement component 1q) to induce immune effector function. To confirm whether the binding ability to FcγRIIa, FcγRIIIa, and C1q was maintained when the CH3 domain variant according to the present invention was introduced into the IgG1 framework, binding kinetics analysis was performed using the Octet® HTX system. The specific implementation process of the binding kinetics analysis was as follows.
[0258] FcγRIIa: After baseline adjustment for 60 seconds with analysis buffer (1X PBS containing 0.25% sodium azide + 0.5% BSA + 0.1% Tween-20) on the FAB2G Biosensor, 100 nM of bispecific antibody was immobilized for 300 seconds, baseline adjustment for another 60 seconds, and serially diluted FcγRIIa (4000, 2000, 1000, 500, 250, 125, 62.5, 0 nM) were bound and dissociated for 60 seconds each. Data Analysis 12.0 software was used to perform K D The value was calculated
[0259]
[0260] FcγRIIIa: After baseline adjustment for 60 seconds with 1X kinetics buffer on the FAB2G Biosensor, 100 nM of dual-specific antibody was immobilized for 300 seconds, baseline adjustment was again performed for 60 seconds, and serially diluted FcγRIIIa (2000, 1000, 500, 250, 125, 62.5, 31.25, 0 nM) were bound and dissociated for 60 seconds each.
[0261]
[0262] C1q: After baseline adjustment for 60 seconds with analysis buffer (1X PBS containing 200 mM NaCl + 0.3% BSA + 0.05% Tween-20) on the FAB2G Biosensor, 100 nM of the dual-specific antibody was immobilized for 300 seconds, baseline adjustment was again performed for 60 seconds, and serially diluted C1q (200, 100, 50, 25, 12.5, 6.25, 3.125, 0 nM) was bound for 30 seconds and dissociated for 60 seconds.
[0263]
[0264] Example 10. Analysis of FcRn binding kinetics
[0265]
[0266] The Fc region (CH2-CH3) of IgG1 plays an important role in improving the half-life of antibodies by interacting with FcRn and mediating the recycling of antibodies. To confirm whether the binding ability to FcRn was maintained when the CH3 domain variant according to the present invention was introduced into a bispecific antibody, a binding kinetics analysis was performed using the Octet® HTX system. The specific implementation process of the binding kinetics analysis was as follows. After adjusting the baseline for 60 seconds with 1x kinetics buffer on the FAB2G Biosensor, the bispecific antibody diluted to 100 nM was immobilized for 300 seconds, and the baseline was adjusted for 180 seconds with the analysis buffer at pH 6.0, and then serially diluted FcRn (1600, 800, 400, 200, 100, 50, 250 nM) was bound for 30 seconds and dissociated for 60 seconds. Data Analysis 12.0 software was used to analyze K D The value was calculated
[0267]
[0268]
[0269] According to the present invention, a heterodimer comprising a CH3 domain with an increased heterodimer formation yield can be provided.
[0270] In addition, according to the present invention, by introducing an asymmetric amino acid mutation into the CH3 domain of the heavy chain constant region, the formation of homodimers occurring during the production of dual-specific antibodies can be minimized, and the yield of heterodimer formation can be improved.
[0271] In addition, the bispecific antibody manufactured using the CH3 domain variant of the heavy chain constant region according to the present invention maintains the target antigen binding ability of the existing wild-type antibody and the inherent function of the heavy chain constant region (Fc: Hinge-CH2-CH3), i.e., the binding ability to Fcγ receptor (FcγR, Fcγ Receptor), complement protein (C1q, Complement component 1q), and FcRn (Neonental Fc receptor), thereby maintaining antibody-dependent immune effector function and half-life in blood.
[0272] Furthermore, the present invention is a bispecific antibody format that improves non-specific binding or homodimer formation of heavy and light chains in existing bispecific antibody formats that simultaneously bind first and second antigens. By introducing an asymmetric amino acid mutation into the CH3 domain of the heavy chain constant region and introducing another asymmetric amino acid mutation into the CH3 domain of the antibody variable region additionally applied to the company's bispecific antibody format, the formation of homodimers that occur during the production of bispecific antibodies can be minimized and the yield of heterodimer formation can be improved.
[0273]
[0274] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0275]
[0276]
[0277] Electronic file attached.
Claims
1. A heterodimer comprising a first heavy chain CH3 domain and a second heavy chain CH3 domain, The first heavy chain CH3 domain or the second heavy chain CH3 domain comprises one or more amino acid substitutions (according to the EU index) at a position selected from the group consisting of: (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R; (2) The amino acid at position D399 is substituted with W, F, Y or H; (3) amino acid at position K360, K370 or K439 is substituted with Q, N, E or D; and (3) Substitution of the amino acid at position K409 with A, V, T or S; A heterodimer in which the first heavy chain CH3 domain and the second heavy chain CH3 domain combine to form a dimer.
2. A heterodimer in which the amino acid at position Q347, E356 or E357 in the first heavy chain CH3 domain is substituted with K or R, or the amino acid at position D399 is substituted with W, F, Y or H.
3. A heterodimer in which the amino acid at position K360, K370 or K439 in the second heavy chain CH3 domain is substituted with Q, N, E or D, or the amino acid at position K409 is substituted with A, V, T or S.
4. A heterodimer comprising Q347K or Q347R among the first heavy chain CH3 domains and K360Q, K360N, K360E, or K360D among the second heavy chain CH3 domains in the first paragraph.
5. A heterodimer comprising E357K or E357R among the first heavy chain CH3 domains and K370Q, K370N, K370E, or K370D among the second heavy chain CH3 domains in the first paragraph.
6. A heterodimer comprising E356K or E356R among the first heavy chain CH3 domains and K439Q, K439N, K439E, or K439D among the second heavy chain CH3 domains in the first paragraph.
7. A heterodimer comprising D399W, D399F, D399Y or D399H among the first heavy chain CH3 domains and K409A, K409T, K409V or K409S among the second heavy chain CH3 domains in the first paragraph.
8. A heterodimer according to claim 1, further comprising at least one selected from the group consisting of Y349C, S354C, T366S, T366W, L368A, and Y407V among the first heavy chain CH3 domain or the second heavy chain CH3 domain.
9. A fusion protein comprising a heterodimer according to one of claims 1 to 8.
10. A bispecific antibody comprising a first arm binding to a first antigen comprising VH1-CHa-Fc1 and VL1-CLb; and a second arm binding to a second antigen comprising VH2-CH1-Fc2 and VL2-CL. The above VH1 and VH2 are heavy chain variable regions each including the same or different antigen binding regions, The above VL1 and VL2 are light chain variable regions each containing the same or different antigen binding regions, The above CHa comprises an IgG heavy chain constant region or an IgD heavy chain constant region CH1, and an IgG heavy chain constant region CH2 or CH3, The above CLb comprises at least one selected from the group consisting of CL1 comprising an IgG light chain constant region λ or κ and IgG heavy chain constant regions CH1, CH2, CH3, The above CH1 is the IgG heavy chain constant region CH1, and CL is the IgG light chain constant region CL, The Fc1 of the first arm and the Fc2 of the second arm combine to form a heavy chain constant region dimer, A bispecific antibody comprising a heterodimer comprising a first heavy chain CH3 domain and a second heavy chain CH3 domain, wherein CH3 of the CHa, Fc1 of the first arm or Fc2 of the second arm comprises one or more amino acid substitutions (according to the EU index) at positions selected from the group consisting of: (1) Substitution of the amino acid at position Q347, E356 or E357 with K or R; (2) The amino acid at position D399 is substituted with W, F, Y or H; (3) amino acid at position K360, K370 or K439 is substituted with Q, N, E or D; and (3) The amino acid at position K409 is substituted with A, V, T, or S.
11. A dual-specific antibody in claim 10, wherein the amino acid at position Q347, E356 or E357 in the first heavy chain CH3 domain is substituted with K or R, or the amino acid at position D399 is substituted with W, F, Y or H.
12. A dual-specific antibody in claim 10, wherein the amino acid at position K360, K370 or K439 in the second heavy chain CH3 domain is substituted with Q, N, E or D, or the amino acid at position K409 is substituted with A, V, T or S.
13. A dual specific antibody comprising Q347K or Q347R among the first heavy chain CH3 domains and K360Q, K360N, K360E or K360D among the second heavy chain CH3 domains in claim 10.
14. A bispecific antibody comprising E357K or E357R among the first heavy chain CH3 domains and K370Q, K370N, K370E or K370D among the second heavy chain CH3 domains in claim 10.
15. A bispecific antibody comprising E356K or E356R among the first heavy chain CH3 domains and K439Q, K439N, K439E or K439D among the second heavy chain CH3 domains in claim 10.
16. A bispecific antibody comprising D399W, D399F, D399Y or D399H among the first heavy chain CH3 domains and K409A, K409T, K409V or K409S among the second heavy chain CH3 domains in claim 10.
17. A bispecific antibody according to claim 10, further comprising at least one selected from the group consisting of Y349C, S354C, T366S, T366W, L368A, and Y407V among the first heavy chain CH3 domain or the second heavy chain CH3 domain.
18. In the 10th paragraph, a dual specific antibody in which CH3 and CH1 of CHa or CH3 and CL1 of CLb are connected by a linker.
19. A dual specific antibody according to claim 18, wherein the linker comprises residues of 5 to 10 aa.
20. In claim 18, the first and second arms are a dual-specific antibody connected via a hinge.
Citation Information
Patent Citations
Rack and pinion type vehicle door opening and closing device capable of manual and automatic switching
KR1020230119863A
Bispecific Antigen Binding Proteins
US20100316645A1
Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
WO2022150785A2
KR20190015583A
KR20220095163A
Cited By
Binding agents having altered FC-mediated effector functions
WO2025228844A1
